The PD-1 checkpoint inhibitor Opdivo (nivolumab) has been approved by the FDA as an initial treatment for advanced gastric cancer, adding to its approvals as a treatment for melanoma and a number of other cancers.
A new sweat sensor can detect seven inflammatory proteins seen at high levels in patients experiencing the kind of extreme immune reaction seen in COVID-19 and in some flu patients, which researchers hope will speed up treatment.
The researchers found that mutations in KMT2C and KMT2D make non-small cell lung cancer more sensitive to Poly (ADP-ribose) polymerase (PARP) inhibitors, which are already approved for treating prostate, pancreatic, ovarian, and breast cancer patients.
The researchers identified 25 new rare pathogenic variants associated with lung cancer susceptibility and validated five of those variants. Of those five, two variants involved genes with known connections to lung cancer risk, ATM and MPZL2. Three variants involved novel lung cancer susceptibility genes, POMC, STAU2 and MLNR.
The researchers used mRNA technology to code for Cas13a, which destroys parts of the RNA genetic code that viruses use to replicate in cells in the lungs. Using a guide strand, researchers can provide a map that basically tells the Cas13a protein where to attach to the viruses’ RNA and begin to destroy it.
Researchers at the Baylor College of Medicine report that they have found that microbes in the gut may contribute to certain symptoms associated with complex neurological disorders, which also suggests that microbe-inspired therapies may one day help to treat them.
SARS-CoV-2 affects many parts of the body. Although the primary manifestations of COVID-19 involve the respiratory system, gastrointestinal effects may play a critical role in both disease severity and transmission.
The ABCC1 protein has the ability to break down amyloid plaques in Alzheimer’s disease and researchers show in a new study that increasing expression of this gene may even prevent the neurodegenerative disease from developing in the first place.
A team of researchers from Centre de Recherche en Cancerologie de Marseille (CRCM), INSERM in France have developed a new method for capturing the metabolic signature of pancreatic ductal adenocarcinoma to predict clinical outcomes.
The new automation friendly reagents allow laboratories testing for COVID-19 have a tool that allows them to skip the RNA extraction step of the many testing workflows and move directly to PCR amplification.